Picture of blood cells

Open Access research which pushes advances in bionanotechnology

Strathprints makes available scholarly Open Access content by researchers in the Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS) , based within the Faculty of Science.

SIPBS is a major research centre in Scotland focusing on 'new medicines', 'better medicines' and 'better use of medicines'. This includes the exploration of nanoparticles and nanomedicines within the wider research agenda of bionanotechnology, in which the tools of nanotechnology are applied to solve biological problems. At SIPBS multidisciplinary approaches are also pursued to improve bioscience understanding of novel therapeutic targets with the aim of developing therapeutic interventions and the investigation, development and manufacture of drug substances and products.

Explore the Open Access research of SIPBS. Or explore all of Strathclyde's Open Access research...

Review of the quarter's economic trends [July 1976]

Bell, David N. F. and Carruth, Alan and McGilvray, James W. and O'Sullivan, N. and Simpson, David R. F. (1976) Review of the quarter's economic trends [July 1976]. Quarterly Economic Commentary, 2 (1). pp. 1-5. ISSN 0306-7866

[img]
Preview
PDF (FEC_2_1_1976_Economic_Trends)
FEC_2_1_1976_Economic_Trends.pdf
Final Published Version

Download (321kB)| Preview

    Abstract

    The initial recovery phase of the leading economies in the second half of 1975 occurred at a fairly leisurely pace compared to past experience of the upturn. However, the first quarter of 1976 has seen industrial production expanding rapidly in most countries, with an expected rise of 10% over the same period last year. This increases momentum in the world economy has led to revision of official forecasts of many important indicators. The volume of world trade is now expected to rise by 10% this year. Total output, which fell by 1 ½% last year, should increase by 5% this year. Inflation in most countries is now in single figures on an annual rate basis. Profit levels have improved considerably: so far there is little evidence of a recovery in investment in plant and machinery.